The Effect of a Novel Serine Protease Inhibitor on Inflammation and Intestinal Permeability in a Murine Colitis Transfer Model

Background: A protease/antiprotease disbalance is observed in inflammatory bowel diseases (IBD). We therefore studied the effect of the novel serine protease inhibitor UAMC-00050 on intestinal inflammation and permeability in a chronic colitis T cell transfer mouse model to get further insight into the regulation of T cell-mediated immunopathology. Methods: Colitis was induced in severe combined immunodeficient (SCID) mice, by the adoptive transfer of CD4+CD25−CD62L+ T cells. Animals were treated intraperitoneally (i.p.) 2x/day with vehicle or UAMC-00050 (5 mg/kg) from week 2 onwards. Colonic inflammation was assessed by clinical parameters, colonoscopy, macroscopy, microscopy, myeloperoxidase activity and cytokine expression levels. At week 4, 4 kDa FITC-dextran intestinal permeability was evaluated and T helper transcription factors, protease-activated receptors and junctional proteins were quantified by RT-qPCR. Results: Adoptive transfer of CD4+CD25−CD62L+ T cells resulted in colonic inflammation and an altered intestinal permeability. The serine protease inhibitor UAMC-00050 ameliorated both the inflammatory parameters and the intestinal barrier function. Furthermore, a decrease in colonic mRNA expression of Tbet and PAR4 was observed in colitis mice after UAMC-00050 treatment. Conclusion: The beneficial effect of UAMC-00050 on inflammation was apparent via a reduction of Tbet, IFN-γ, TNF-α, IL-1β and IL-6. Based on these results, we hypothesize a pivotal effect of serine protease inhibition on the Th1 inflammatory profile potentially mediated via PAR4.

[1]  I. De Meester,et al.  Local Colonic Administration of a Serine Protease Inhibitor Improves Post-Inflammatory Visceral Hypersensitivity in Rats , 2021, Pharmaceutics.

[2]  M. Grover,et al.  Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review , 2021, Therapeutic advances in gastroenterology.

[3]  John T. Chang,et al.  Pathophysiology of Inflammatory Bowel Diseases. , 2020, The New England journal of medicine.

[4]  S. Mehandru,et al.  The intestinal barrier, an arbitrator turned provocateur in IBD , 2020, Nature Reviews Gastroenterology & Hepatology.

[5]  L. Moons,et al.  A novel serine protease inhibitor as potential treatment for dry eye syndrome and ocular inflammation , 2020, Scientific Reports.

[6]  Patrice D Cani,et al.  Mucus barrier, mucins and gut microbiota: the expected slimy partners? , 2020, Gut.

[7]  A. Paterson,et al.  Increased Intestinal Permeability is Associated with Later Development of Crohn's Disease. , 2020, Gastroenterology.

[8]  Michel-Edwar Mickael,et al.  "Retinoid-related orphan receptor RORγt in CD4+T cell-mediated intestinal homeostasis and inflammation." , 2020, The American journal of pathology.

[9]  J. Yearley,et al.  IL-23 and IL-2 activation of STAT5 is required for optimal IL-22 production in ILC3s during colitis , 2020, Science Immunology.

[10]  E. Maguin,et al.  Serine proteases at the cutting edge of IBD: Focus on gastrointestinal inflammation , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  A. Denadai-Souza,et al.  The interplay between genetic risk factors and proteolytic dysregulation in the pathophysiology of inflammatory bowel disease. , 2020, Journal of Crohn's & colitis.

[12]  T. Breugelmans,et al.  In depth study of transmembrane mucins in association with intestinal barrier dysfunction during the course of T cell transfer and DSS-induced colitis. , 2020, Journal of Crohn's & colitis.

[13]  J. Wallace,et al.  Active thrombin produced by the intestinal epithelium controls mucosal biofilms , 2019, Nature Communications.

[14]  R. Lechler,et al.  Protease Activated Receptor 4 as a Novel Modulator of Regulatory T Cell Function , 2019, Front. Immunol..

[15]  S. Francque,et al.  Identifying Therapeutic Targets for Sepsis Research: A Characterization Study of the Inflammatory Players in the Cecal Ligation and Puncture Model , 2018, Mediators of inflammation.

[16]  A. Lambeir,et al.  Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post‐inflammatory rat model for irritable bowel syndrome , 2018, British journal of pharmacology.

[17]  S. Durum,et al.  Cytokine Tuning of Intestinal Epithelial Function , 2018, Front. Immunol..

[18]  M. Kaplan,et al.  Effector T Helper Cell Subsets in Inflammatory Bowel Diseases , 2018, Front. Immunol..

[19]  M. Hollenberg,et al.  Functional Proteomic Profiling of Secreted Serine Proteases in Health and Inflammatory Bowel Disease , 2018, Scientific Reports.

[20]  S. Vermeire,et al.  The intestinal barrier: a fundamental role in health and disease , 2017, Expert review of gastroenterology & hepatology.

[21]  A. Lambeir,et al.  Regulation of intestinal permeability: The role of proteases , 2017, World journal of gastroenterology.

[22]  A. Denadai-Souza,et al.  P100 Intestinal epithelial cells under endoplasmic reticulum stress boosts serine proteolytic activity and modulates barrier function. , 2017, Journal of Crohn's & colitis.

[23]  A. Lambeir,et al.  Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases , 2016, World journal of gastroenterology.

[24]  M. Kronenberg,et al.  When Insult Is Added to Injury: Cross Talk between ILCs and Intestinal Epithelium in IBD , 2016, Mediators of inflammation.

[25]  N. Vergnolle.  Protease inhibition as new therapeutic strategy for GI diseases , 2016, Gut.

[26]  V. Magdolen,et al.  The first potent diphenyl phosphonate KLK4 inhibitors with unexpected binding kinetics , 2015 .

[27]  J. Sallenave,et al.  Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci , 2015, Microbial Cell Factories.

[28]  N. Ruyssers,et al.  Treatment with Egg Antigens of Schistosoma mansoni Ameliorates Experimental Colitis in Mice Through a Colonic T-cell–dependent Mechanism , 2015, Inflammatory bowel diseases.

[29]  J. Timmermans,et al.  Worm Proteins of Schistosoma mansoni Reduce the Severity of Experimental Chronic Colitis in Mice by Suppressing Colonic Proinflammatory Immune Responses , 2014, PloS one.

[30]  I. Carroll,et al.  Enteric bacterial proteases in inflammatory bowel disease- pathophysiology and clinical implications. , 2013, World journal of gastroenterology.

[31]  S. Stroobants,et al.  Colonoscopy and µPET/CT are Valid Techniques to Monitor Inflammation in the Adoptive Transfer Colitis Model in Mice , 2013, Inflammatory bowel diseases.

[32]  Gilles Dietrich,et al.  Food-Grade Bacteria Expressing Elafin Protect Against Inflammation and Restore Colon Homeostasis , 2012, Science Translational Medicine.

[33]  Stefan Wyder,et al.  Genetic Evidence Supporting the Association of Protease and Protease Inhibitor Genes with Inflammatory Bowel Disease: A Systematic Review , 2011, PloS one.

[34]  T. Wittmann,et al.  Intracolonic infusion of fecal supernatants from ulcerative colitis patients triggers altered permeability and inflammation in mice: Role of cathepsin G and protease‐activated receptor‐4 , 2011, Inflammatory bowel diseases.

[35]  R. Takayanagi,et al.  CD4+CD25+ Regulatory T Cells Suppress Th17-Responses in an Experimental Colitis Model , 2011, Digestive Diseases and Sciences.

[36]  J. Sallenave,et al.  Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis. , 2010, Gastroenterology.

[37]  W. Paul,et al.  Peripheral CD4+ T‐cell differentiation regulated by networks of cytokines and transcription factors , 2010, Immunological reviews.

[38]  A. Fasano,et al.  Membrane-anchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestine , 2010, Proceedings of the National Academy of Sciences.

[39]  M. Hollenberg,et al.  Serine proteases decrease intestinal epithelial ion permeability by activation of protein kinase Czeta. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[40]  T. Wittmann,et al.  Luminal cathepsin g and protease-activated receptor 4: a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis. , 2009, The American journal of pathology.

[41]  A. Loukas,et al.  Therapeutic potential of helminth soluble proteins in TNBS‐induced colitis in mice , 2009, Inflammatory bowel diseases.

[42]  J. Foekens,et al.  Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties. , 2007, Journal of medicinal chemistry.

[43]  Y. Naito,et al.  Anti-tryptase treatment using nafamostat mesilate has a therapeutic effect on experimental colitis , 2006, Scandinavian journal of gastroenterology.

[44]  Michael C. Wendl,et al.  Argonaute—a database for gene regulation by mammalian microRNAs , 2005, BMC Bioinformatics.

[45]  J. Wallace,et al.  A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  N. Vergnolle,et al.  Evidence for the presence of functional protease activated receptor 4 (PAR4) in the rat colon , 2004, Gut.

[47]  E. van Marck,et al.  Concurrent infection with Schistosoma mansoni attenuates inflammation induced changes in colonic morphology, cytokine levels, and smooth muscle contractility of trinitrobenzene sulphonic acid induced colitis in rats , 2003, Gut.

[48]  J. Wallace,et al.  Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. , 2002, The American journal of pathology.

[49]  B. Guiard,et al.  Proteinases and proteinase-activated receptor 2: a possible role to promote visceral hyperalgesia in rats. , 2002, Gastroenterology.

[50]  Y. Fujiyama,et al.  Treatment of ulcerative colitis with camostat mesilate, a serine protease inhibitor. , 1993, Internal medicine.

[51]  J. Turner,et al.  The intestinal epithelial barrier: a therapeutic target? , 2017, Nature Reviews Gastroenterology &Hepatology.

[52]  A. Nebreda,et al.  Analysis of Intestinal Permeability in Mice , 2014 .

[53]  荻野 治栄.  CD4[+]CD25[+] regulatory T cells suppress Th17-responses in an experimental colitis model , 2011 .

[54]  B. Boehm,et al.  Cathepsin G: roles in antigen presentation and beyond. , 2010, Molecular immunology.

[55]  T. Yoshikawa,et al.  Basic and translational research on proteinase-activated receptors: implication of proteinase/proteinase-activated receptor in gastrointestinal inflammation. , 2008, Journal of pharmacological sciences.

[56]  磯崎 豊.  Anti-tryptase treatment using nafamostat mesilate has a therapeutic effect on experimental colitis , 2006 .

[57]  G. Rogler,et al.  P 100 Intestinal epithelial cells under endoplasmic reticulum stress boosts serine proteolytic activity and modulates barrier function , 2022 .